High Court Preserves Abortion Pill Access

Supreme Court Upholds Abortion Pill Access

The U.S. Supreme Court on Thursday ensured that the abortion pill mifepristone can continue to be prescribed via telemedicine and dispensed by mail.

This decision temporarily restores a 2023 federal rule, issued by the U.S. Food and Drug Administration (FDA), which had made access to the medication easier.

The ruling came in response to requests from two manufacturers of mifepristone, Danco Laboratories and GenBioPro, to lift a lower court's block on the FDA rule while a legal challenge from Republican-governed Louisiana proceeds.

The Supreme Court's brief, unsigned order did not provide reasoning, a common practice for emergency actions. Conservative Justices Samuel Alito and Clarence Thomas dissented. The New Orleans-based 5th U.S. Circuit Court of Appeals had previously ordered the reinstatement of an older federal rule requiring an in-person clinician visit for mifepristone. This appellate decision was appealed by the drug manufacturers.

This case marks another instance where abortion access has reached the Supreme Court following its 2022 decision in Dobbs v. Jackson Women's Health Organization , which overturned Roe v. Wade . Mifepristone is utilized in approximately 64% of abortions in the United States. The ongoing legal battles occur amidst the upcoming November U.S. congressional elections.